Weekly Research Analysts’ Ratings Updates for Cullinan Therapeutics (CGEM)

A number of firms have modified their ratings and price targets on shares of Cullinan Therapeutics (NASDAQ: CGEM) recently:

• 12/9/2025 – Cullinan Therapeutics had its price target raised by analysts at Wedbush from $25.00 to $34.00. They now have an “outperform” rating on the stock.
• 12/8/2025 – Cullinan Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Cullinan Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Cullinan Therapeutics had its price target raised by analysts at BTIG Research from $32.00 to $38.00. They now have a “buy” rating on the stock.
• 11/22/2025 – Cullinan Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/20/2025 – Cullinan Therapeutics was given a new $26.00 price target on by analysts at New Street Research.
• 11/20/2025 – Cullinan Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
• 11/20/2025 – Cullinan Therapeutics had its price target raised by analysts at HC Wainwright from $24.00 to $26.00. They now have a “buy” rating on the stock.

Insider Buying and Selling at Cullinan Therapeutics

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 4,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $12.30, for a total transaction of $49,200.00. Following the completion of the sale, the insider owned 138,004 shares of the company’s stock, valued at approximately $1,697,449.20. The trade was a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Lynx1 Capital Management Lp purchased 626,043 shares of Cullinan Therapeutics stock in a transaction on Thursday, October 9th. The stock was bought at an average price of $6.70 per share, with a total value of $4,194,488.10. Following the transaction, the insider owned 8,271,786 shares of the company’s stock, valued at approximately $55,420,966.20. This represents a 8.19% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 1,874,057 shares of company stock worth $13,325,286 in the last quarter. Corporate insiders own 6.07% of the company’s stock.

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.